Yan Xie

Dr. Yan Xie

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2025 in Allergy
Verified
Journal Article
Open access
QFQin-Wei Fu
Qin-Wei Fu
PLPeng Liu
Peng Liu
YRYan Ruan
Yan Ruan
XLXin-Rong Li
Xin-Rong Li
LZLan-Zhi Zhang
Lan-Zhi Zhang
QZQinxiu Zhang
Qinxiu Zhang
Allergic rhinitis (AR) is a prevalent chronic condition that significantly impacts patients' quality of life and poses challenges to effective management. Traditional Chinese medicine (TCM) offers a holistic approach, emphasizing syndrome differentiation, individualized care, and natural treatment strategies. To develop comprehensive evidence‐based guidelines for AR management using TCM interventions, incorporating rigorous evidence assessment and expert consensus. The guidelines were developed using the GRADE‐TCM framework, analyzing 351 randomized controlled trials (RCTs) involving 43,276 participants. Supplementary evidence from published textbooks, standardized documents, ancient literature, and TCM medical records was incorporated. Five rounds of expert consensus, involving 80 expert person‐times and over 10,000 valid responses, refined the recommendations. The guidelines provide 32 recommendations covering four primary TCM syndromes (Deficiency‐cold of Lung Qi , Spleen Qi Deficiency and Weakness, Kidney‐ yang Deficiency, and Latent Heat in Lung Meridian) which are mainly involved in AR. These recommendations include both internal interventions (such as herbal and patent medicines) and external therapies (such as acupuncture, moxibustion, and other acupoint‐based treatment). Of these interventions, 10 received strong recommendations, while 22 were classified as weak recommendations. TCM treatments demonstrated significant efficacy in alleviating AR symptoms, reducing recurrence, and improving quality of life. Additionally, TCM can complement conventional AR treatments by reducing the need for pharmacological therapy while maintaining a favorable safety profile. The guidelines integrate classical TCM principles with modern evidence‐based methodologies, offering a structured framework for AR management. They serve as clinical references for practitioners worldwide, supporting a promising approach to AR treatment. Future updates will incorporate emerging evidence and real‐world clinical data to further optimize the role of TCM in AR management.

6 March 2025 in BMC Public Health
Verified
Journal Article
Open access
PDF file
LLLinZhi Liao
LinZhi Liao
HWHanYu Wang
HanYu Wang
WCWanLing Cui
WanLing Cui
QZQi Zhang
Qi Zhang
XHXiaoQuan He
XiaoQuan He
YXYan Xie
Yan Xie
Laryngeal cancer (LC), as a common head and neck tumor, significantly impacts the quality of life. Utilizing data from the 2021 Global Burden of Disease (GBD) study, we sought to delve deeply into the global LC burden experienced by individuals aged 55 and older from 1990 to 2021 at the global, regional, and national levels. This research encompassed three key indicators: incidence rate, mortality, and disability-adjusted life years (DALYs). Based on the GBD 2021 database, we selected data from 204 countries and regions covering the period from 1990 to 2021 for individuals aged 55 and above. We analyzed LC’s performance in terms of incidence, mortality, and DALYs, calculating the age-standardized rates and the mean average annual percent change (AAPC) at global, regional, and national levels. In our analysis of global trends, we carefully considered multiple variables including age, sex, and the socio-demographic index (SDI). Furthermore, we assessed potential risk factors for LC-associated DALYs and made prospective predictions for the possible scenario by 2035. Globally, the age-standardized DALY rate of LC among adults aged 55 years and older has undergone significant changes. Specifically, this rate dropped sharply from 245.89 cases per 100,000 people in 1990 to 153.76 cases per 100,000 people in 2021, with an AAPC showing a decreasing trend of -2.916. Simultaneously, the age-standardized incidence rate and mortality rate also exhibited a similar downward trend. From a regional perspective, South Asia ranked highest in relevant indicators in 2021, reporting a death toll of 29,258.96, confirmed cases of 34,234.23, and DALYs related to LC reaching 709,622.00. In contrast, the figures in Oceania were the lowest, with only 26.23 deaths, 29.53 incident cases, and 609.09 DALYs. When divided according to the quintiles of the SDI, in 2021, the medium-high SDI led in incidence rates, while the low SDI ranked last. However, in terms of mortality and DALY rates, medium-low SDI topped the list, with high SDI being the lowest. In terms of gender differences, in 2021, the age-standardized DALY rate of LC in males was approximately 7.13 times that of females, with the former reaching 282.12 cases per 100,000 people and the latter only 39.59 cases per 100,000 people. Among all age groups, a notable decrease was observed in the age-specific incidence rate and DALY for adults aged 60–64 years, with AAPC values of -0.123 (95% CI: -0.130 to -0.116) and − 3.553 (95% CI: -3.620 to -3.486), respectively. Similarly, the mortality rate for adults aged 65–69 years also showed a significant decline, with an AAPC of -0.123 (95% CI: -0.127 to -0.118). Additionally, tobacco has been revealed as the most important risk factor affecting the mortality and DALY of LC in adults aged 55 years and older. Looking ahead, it is predicted that by 2035, the incidence rate, mortality rate, and DALY rate of LC among people over 55 years old will continue to decline. Despite the current data and future predictions indicating a decline in the global age-standardized incidence rate, the absolute number of estimates continues to increase. Therefore, we advocate that cancer prevention strategies should place greater emphasis on vigorously addressing modifiable risk factors, particularly for the male population, which requires special attention and scientific intervention.

21 October 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
LWLing Wang
Ling Wang
LLLinZhi Liao
LinZhi Liao
JHJueZhi Huang
JueZhi Huang
QZQi Zhang
Qi Zhang
YXYanQing Xiong
YanQing Xiong
YXYan Xie
Yan Xie
Background: Thyroid cancer (TC) has shown dynamic changes in its global burden over the past decades. This study aimed to evaluate trends in incidence, mortality, and disability-adjusted life years (DALYs) of TC among middle-aged and elderly adults across 204 countries and territories from 1990 to 2021. Methods: Data were extracted from the Global Burden of Disease Study 2021. Age-standardized rates (ASRs) of incidence, death, and DALYs, estimated annual percentage change (EAPC), and the sociodemographic index (SDI) were used to quantify trends. A Bayesian age-period-cohort (BAPC) model was employed to predict future burden through 2035, and global risk-attributable factors were assessed. Results: Globally, TC incidence cases among adults aged 55 and older increased by 185% from 1990 to 2021, with deaths and DALYs rising by 116 and 108%, respectively. The age-standardized incidence rate rose significantly (EAPC = 0.95), while mortality and DALY rates slightly declined. Most regions showed rising incidence, with the exception of Central Europe. Females consistently exhibited higher TC burden, but the gender gap is gradually narrowing. Peak incidence occurred at ages 70–74 for females and 85–89 for males in 2021. High body mass index (BMI) emerged as the leading modifiable risk factor. Conclusion: The rising burden of thyroid cancer in aging populations calls for integrated health policies emphasizing prevention, early detection, and public education. Efforts should focus on reducing modifiable risks, particularly high BMI, and developing age- and sex-specific interventions. Addressing gender disparities and regional inequalities should also be central to global and national cancer control strategies.

26 April 2023 in Frontiers in Surgery
Verified
Journal Article
Open access
YXYan Xie
Yan Xie
SWShiqi Wu
Shiqi Wu
WCWanling Cui
Wanling Cui
DZDandi Zeng
Dandi Zeng
FCFeifei Chen
Feifei Chen
LJLuYun Jiang
LuYun Jiang
Objective: The objectives of this study were to analyze rhinogenic headache, i.e., noninflammatory frontal sinus headache, a headache caused by bony obstruction of the frontal sinus drainage channels that receives relatively insufficient attention clinically, and to propose endoscopic frontal sinus opening surgery as a treatment based on the etiology.Study Design: Case series.Setting: From the data of patients with noninflammatory frontal sinus headache who underwent endoscopic frontal sinus surgery in Hospital of Chengdu University of Traditional Chinese Medicine during 2016–2021, data for three cases with detailed postoperative follow-up data were extracted for case series reports.Methods: This report provides detailed information on three patients with noninflammatory frontal sinusitis headache. Treatment options include surgery and rechecking, with the visual analogue scale (VAS) scores of preoperative and postoperative symptoms, CT, and endoscopic images. Three patients had common characteristics: the clinical manifestations were recurrent or persistent with pain and discomfort in the forehead area, but there was no nasal obstruction or runny nose; the paranasal sinus CT revealed no signs of inflammation in the sinuses but suggested bony obstruction of the drainage channel of the frontal sinus.Results: All three patients had recovery from headache, nasal mucosal recovery, and patent frontal sinus drainage. The recurrence rate of forehead tightness and discomfort or pain was 0.Conclusion: Noninflammatory frontal sinus headache does exist. Endoscopic frontal sinus opening surgery is a feasible treatment modality that can largely or even completely eliminate the stuffy swelling and pain in the forehead. The diagnosis and surgical indications for this disease are based on a combination of anatomical abnormalities and clinical symptoms.

30 May 2024 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
YXYan Xie
Yan Xie
FLFangqi Liang
Fangqi Liang
LZLi Zhou
Li Zhou
QCQing Chen
Qing Chen
FCFeifei Chen
Feifei Chen
LJLuYun Jiang
LuYun Jiang
Background: Functional endoscopic sinus surgery is a principal option for treating chronic rhinosinusitis with nasal polyps (CRSwNP) after medication failures. Unfortunately, some patients still have unsatisfactory postoperative recovery. The type of inflammatory cell infiltration in nasal polyp tissue has been reported available for recurrence prediction. As it is invasive and time-consuming, this technique is hard to promote clinically under the existing technical conditions. And during the course of clinical treatment, we have noted that differences in the postoperative recurrence rate of patients present among different traditional Chinese medicine syndrome types. Methods and analysis: This is a non-randomized, single-center, and prospective cohort study started in Chengdu Sichuan Province, People’s Republic of China, in January 2021. A total of 200 participants will be recruited from patients who are diagnosed with CRSwNP and prepared for functional endoscopic sinus surgery. We collect preoperative data which includes general information, medical history, TCM syndromes, visual analogue scale (VAS) of subjective symptoms, Lund-Kennedy endoscopic score, and Lund-Mackay score of computed tomography (CT) scanning of sinuses. We acquire the VAS score and Lund-Kennedy score of subjective symptoms through multiple planned follow-up after surgery. After 1 year of follow-up, the recurrence rate will be calculated, and the curative effect will be assessed. Meanwhile, the patients’ pathological sections will be sorted out, and inflammatory cell infiltration will be analyzed. Statistical analysis will be carried out to evaluate the correlation among CRSwNP recurrence and TCM syndrome types and tissue inflammatory cell infiltration types. Then we will establish a predictive model for CRSwNP recurrence. Analyses of survey data include descriptive and inferential statistical approaches. Discussion: This is the first prospective cohort study on investigating the correlation of CRSwNP recurrence with TCM syndrome types and tissue inflammatory cell infiltration types. Through this study, we hope to discover a new and simple, effective, and noninvasive way to predict the recurrence rate rapidly after CRSwNP and provide reference for the intervention timing of traditional Chinese medicine application, thereby achieving customized diagnosis and treatment, minimizing risks of surgical events, and delaying postoperative recurrence of CRSwNP. Systematic review registration: PROSPERO ChiCTR2100041646.

14 November 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
LWLing Wang
Ling Wang
LLLinZhi Liao
LinZhi Liao
JHJueZhi Huang
JueZhi Huang
QZQi Zhang
Qi Zhang
YXYanQing Xiong
YanQing Xiong
YXYan Xie
Yan Xie
• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others. • Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.